2,280 press releases in English indexed under biotech & pharma.
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC
LONDON, Oct. 2, 2026 -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in partnership with Jupiter Research LLC, today announced that its Que Medical Inhalation Device (QMID) is available in Australia, following the registration by Australia's Therapeutic...
TORONTO and HOUSTON, Oct. 01, 2026 -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”).
Sarcomatrix Therapeutics Extends Accredited Investor Round to October 31
GRANITE BAY, Calif., Oct. 1, 2026 -- As pharmaceutical and biotechnology sectors navigate evolving global supply chain risks, GMP Labeling Inc. is utilizing Manufacturing Day 2026 to highlight its nearly 40-year history as a domestic manufacturer of critical compliance...
New York, New York--(October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us. You may...
ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.
SAN DIEGO, Oct. 01, 2026 -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
FORT COLLINS, Colo., Oct. 1, 2026 -- CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS)...
NEW YORK and WALTHAM, Mass., Oct. 01, 2026 -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
FOSTER CITY, Calif., Oct. 01, 2026 -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately. The gross proceeds from the offering were approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering were sold by Sagimet.
Fentanyl Phase 2 Trial met all endpoints; Phase 3 planned for H1 2027 CAMBRIDGE, Mass., Oct. 1, 2026 -- Clear Scientific, Inc. today announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates...